ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1705962
Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in rats
Provisionally accepted- 1Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czechia
- 2Department of Chemical Engineering, Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Czech Republic, Prague, Czechia
- 3Institute of Histology and Embryology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czechia
- 4Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Objectives: This study aims to assess the anti-inflammatory properties of cannabigerol (CBG) in collagen-induced arthritis (CIA) model in rats, and to determine which inflammatory signaling pathways it affects. Study design: Rats were randomized into four groups: placebo (PCB) – p.o. treated with 1 mL of 0.9% saline once daily, CBG – p.o. treated with 30 mg of CBG/day, glucocorticoids (GC) – p.o. treated with methylprednisolone 0.5 mg/kg/day, and negative control (CO) – p.o. treated with 1 mL of 0.9% saline once daily. CIA was induced in the PCB, GC, and CBG groups. The effect of CBG was assessed by clinical scoring, paw width measurements, ELISA, and analysis of gene (qPCR) and protein (Western blot) expression of selected inflammatory markers in blood and synovial membrane. Results: Clinical scores showed significant improvement in the CBG vs. PCB on day 29 and in the GC vs. PCB on days 24, 27, and 29. MMP-3 levels in serum were significantly reduced in the GC vs. PCB. CBG demonstrated a selective anti-inflammatory and immunomodulatory profile, notably through the downregulation of key signaling molecules such as TLRs, systemic NF-κB p65, STAT-3, and inflammasome-related components including NLRP1A, NLRP3, AIM2, gasdermin D, and caspase-1. It also reduced IL-1β and TNF expression during the early phase of disease and increased expression of the anti-apoptotic gene BCL-2. Conclusions: Our findings indicate that CBG modulates distinct components of the inflammatory signaling pathways, and its effects translated into significant improvement in clinical scoring based on swelling, erythema, stiffness in rat CIA model.
Keywords: Cannabinoids, Cannabigerol, Rheumatoid arthritis, CIA model, Inflammasome
Received: 15 Sep 2025; Accepted: 20 Oct 2025.
Copyright: © 2025 Šteigerová, Sklenárová, Bazyuk, Záveský, Jelínek, Arora, Stránský, Kučera, Sepodes, Šoóš, Šíma and Slanar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Martin Šíma, martin.sima@lf1.cuni.cz
Ondrej Slanar, ondrej.slanar@lf1.cuni.cz
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.